|
000
| 01041nam 2200229za 4500 |
|---|
| 001 | 9.699195 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210625000254 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150407s2014||||xxc|||||o f|0| 0 eng d |
|---|
| 020 | |a978-1-100-23516-5 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-104/2014E-PDF |
|---|
| 110 | 2 |aPublic Health Agency of Canada. |
|---|
| 245 | 10|aAdvice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine : |h[electronic resource] |
|---|
| 246 | 1 |iAt head of title: |aAdvisory Committee Statement (ACS), National Advisory Committee on Immunization |
|---|
| 260 | |aOttawa - Ontario : |bPublic Health Agency of Canada |cApril 2014. |
|---|
| 300 | |a43p.|bgraphs, references, tables |
|---|
| 590 | |a14-16|b2014-04-17 |
|---|
| 775 | 08|tConseils relatifs à l'utilisation du vaccin multicomposant contre le méningocoque du sérogroupe B (4CMenB) |w(CaOODSP)9.643156 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s664 KB|uhttps://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-104-2014-eng.pdf |
|---|